- Home
- LEGH vs UPB Comparison
LEGH vs UPB Comparison
Compare LEGH & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- UPB
- Stock Information
- Founded
- LEGH 2005
- UPB 2021
- Country
- LEGH United States
- UPB United States
- Employees
- LEGH N/A
- UPB N/A
- Industry
- LEGH Homebuilding
- UPB
- Sector
- LEGH Consumer Discretionary
- UPB
- Exchange
- LEGH Nasdaq
- UPB NYSE
- Market Cap
- LEGH 588.8M
- UPB 521.3M
- IPO Year
- LEGH 2018
- UPB 2024
- Fundamental
- Price
- LEGH $25.28
- UPB $8.78
- Analyst Decision
- LEGH Buy
- UPB Strong Buy
- Analyst Count
- LEGH 2
- UPB 4
- Target Price
- LEGH $29.00
- UPB $56.50
- AVG Volume (30 Days)
- LEGH 64.7K
- UPB 327.1K
- Earning Date
- LEGH 05-12-2025
- UPB 05-06-2025
- Dividend Yield
- LEGH N/A
- UPB N/A
- EPS Growth
- LEGH 14.29
- UPB N/A
- EPS
- LEGH 2.48
- UPB N/A
- Revenue
- LEGH $184,191,000.00
- UPB $2,296,000.00
- Revenue This Year
- LEGH $3.55
- UPB N/A
- Revenue Next Year
- LEGH $8.46
- UPB $0.99
- P/E Ratio
- LEGH $10.21
- UPB N/A
- Revenue Growth
- LEGH N/A
- UPB N/A
- 52 Week Low
- LEGH $20.55
- UPB $5.14
- 52 Week High
- LEGH $29.31
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- LEGH 57.01
- UPB N/A
- Support Level
- LEGH $24.65
- UPB N/A
- Resistance Level
- LEGH $25.54
- UPB N/A
- Average True Range (ATR)
- LEGH 0.58
- UPB 0.00
- MACD
- LEGH 0.14
- UPB 0.00
- Stochastic Oscillator
- LEGH 86.10
- UPB 0.00
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.